Biotron Drug Effective Against
COVID-19 in Animals – Webinar
Biotron Limited – Developing a new class of antiviral therapies
Biotron’s lead compound, BIT225, is in Phase 2 development for the treatment of HIV-1 and Hepatitis C virus infections. Importantly BIT225 inhibits HIV-1 replication in macrophage reservoir cells offering the potential, when used in combination with other anti-retroviral compounds, to eradicate HIV-1. In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.
At the start of the COVID-19 pandemic, Biotron commenced a program to develop an antiviral drug to treat SARS-CoV-2 infection. BIT225 demonstrated substantial and clinically meaningful efficacy against SARS-CoV-2 in early stage research studies. The identification of BIT225’s antiviral activity against SARS-CoV-2 has greatly accelerated the clinical, regulatory and licencing pathway of the Company’s COVID-19 program.
In addition, the Company has a robust preclinical pipeline, including an impressive portfolio of compounds with activity against a broad range of viral diseases.
